As the immune checkpoint inhibitors progress into more tumor types, earlier lines of therapy and combination regimens, cost concerns are pushing demand for biomarkers to help guide patient selection.
At the American Society of Clinical Oncology annual meeting, held in Chicago May 29-June 2, there was continued debate over...